Viridian Therapeutics, Inc./DE Increase (Decrease) in Contract with Customer, Liability
Viridian Therapeutics, Inc./DE (VRDN) reported Increase (Decrease) in Contract with Customer, Liability of -$144.00 thousand for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2025-08-06
- Viridian Therapeutics, Inc./DE increase (decrease) in contract with customer, liability for the quarter ending 2025-06-30 was -$72.00K.
- Viridian Therapeutics, Inc./DE increase (decrease) in contract with customer, liability for the quarter ending 2025-03-31 was -$72.00K.
- Viridian Therapeutics, Inc./DE increase (decrease) in contract with customer, liability for the quarter ending 2024-12-31 was -$72.00K.
- Viridian Therapeutics, Inc./DE increase (decrease) in contract with customer, liability for the quarter ending 2024-09-30 was -$72.00K.
- Viridian Therapeutics, Inc./DE increase (decrease) in contract with customer, liability for fiscal 2024 was -$288.00K.
- Viridian Therapeutics, Inc./DE increase (decrease) in contract with customer, liability for fiscal 2023 was -$288.00K.
- Viridian Therapeutics, Inc./DE increase (decrease) in contract with customer, liability for fiscal 2022 was -$288.00K, a 145.28% decline from fiscal 2021.
- Viridian Therapeutics, Inc./DE increase (decrease) in contract with customer, liability for fiscal 2021 was $636.00K.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 3 month as first filed | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|---|
| 2025-06-30 | -$72.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$144.00K 10-Q · filed 2025-08-06 | -$216.00K derived: sum of 3 quarters · filed 2025-08-06 | -$288.00K derived: sum of 4 quarters · filed 2025-08-06 | |
| 2025-03-31 | -$72.00K 10-Q · filed 2025-05-06 | -$144.00K derived: sum of 2 quarters · filed 2025-05-06 | -$216.00K derived: sum of 3 quarters · filed 2025-05-06 | -$288.00K derived: sum of 4 quarters · filed 2025-08-06 | |
| 2024-12-31 | -$72.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$144.00K derived: sum of 2 quarters · filed 2025-03-03 | -$216.00K derived: sum of 3 quarters · filed 2025-08-06 | -$288.00K 10-K · filed 2025-03-03 | |
| 2024-09-30 | -$72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$144.00K derived: sum of 2 quarters · filed 2025-08-06 | -$216.00K 10-Q · filed 2024-11-12 | -$288.00K derived: sum of 4 quarters · filed 2025-08-06 | |
| 2024-06-30 | -$72.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$144.00K 10-Q · filed 2025-08-06 | -$216.00K derived: sum of 3 quarters · filed 2025-08-06 | -$288.00K derived: sum of 4 quarters · filed 2025-08-06 | |
| 2024-03-31 | -$72.00K 10-Q · filed 2025-05-06 | -$144.00K derived: sum of 2 quarters · filed 2025-05-06 | -$216.00K derived: sum of 3 quarters · filed 2025-05-06 | -$288.00K derived: sum of 4 quarters · filed 2025-05-06 | |
| 2023-12-31 | -$72.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$144.00K derived: sum of 2 quarters · filed 2025-03-03 | -$216.00K derived: sum of 3 quarters · filed 2025-03-03 | -$288.00K 10-K · filed 2025-03-03 | |
| 2023-09-30 | -$72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$144.00K derived: sum of 2 quarters · filed 2024-11-12 | -$216.00K 10-Q · filed 2024-11-12 | -$288.00K derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-06-30 | -$72.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$144.00K 10-Q · filed 2024-08-08 | -$216.00K derived: sum of 3 quarters · filed 2025-03-03 | -$288.00K derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-03-31 | -$72.00K 10-Q · filed 2024-05-08 | $2.58M 10-Q · filed 2023-05-10 | -$144.00K derived: sum of 2 quarters · filed 2025-03-03 | -$216.00K derived: sum of 3 quarters · filed 2025-03-03 | -$288.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$72.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$144.00K derived: sum of 2 quarters · filed 2025-03-03 | -$216.00K derived: sum of 3 quarters · filed 2025-03-03 | -$288.00K 10-K · filed 2025-03-03 | |
| 2022-09-30 | -$72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$144.00K derived: sum of 2 quarters · filed 2023-11-13 | -$216.00K 10-Q · filed 2023-11-13 | -$287.00K derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | -$72.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$144.00K 10-Q · filed 2023-08-08 | -$215.00K derived: sum of 3 quarters · filed 2024-02-27 | -$287.00K derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | -$72.00K 10-Q · filed 2023-05-10 | -$143.00K derived: sum of 2 quarters · filed 2024-02-27 | -$215.00K derived: sum of 3 quarters · filed 2024-02-27 | $713.00K derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | -$71.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$143.00K derived: sum of 2 quarters · filed 2024-02-27 | $785.00K derived: sum of 3 quarters · filed 2024-02-27 | $636.00K 10-K · filed 2024-02-27 | |
| 2021-09-30 | -$72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $856.00K derived: sum of 2 quarters · filed 2022-11-14 | $707.00K 10-Q · filed 2022-11-14 | $707.00K derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $928.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $779.00K 10-Q · filed 2022-08-15 | $779.00K derived: sum of 3 quarters · filed 2022-08-15 | ||
| 2021-03-31 | -$149.00K 10-Q · filed 2022-05-13 | -$149.00K derived: sum of 2 quarters · filed 2022-05-13 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $0.00 10-K · filed 2022-03-11 | |||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |